242 results about "Acropustulosis" patented technology

The invention relates to the technical field of compositions, in particular to an anti-aging composition for increasing corium layer collagen and a preparation method of the anti-aging composition. Comprising the following steps: preparing sargassum fusiforme polysaccharide; preparing a composite sargassum fusiforme polysaccharide stabilizer; and compounding and preparing the traditional Chinese medicine extract. The anti-aging composition is prepared by compounding the balm extract, the pistacia chinensis extract, the mulberry extract, the collagen tripeptide and the sargassum fusiforme polysaccharide, all the components are properly compounded, the obtained anti-aging composition and oral liquid are not prone to precipitation in the storage process, loss of nutritional ingredients is avoided, and the anti-aging effect is good. According to the present invention, the components have the obvious synergistic effect, such that the collagen secretion can be promoted while the oxidative stress, the collagen degradation and the skin inflammation can be inhibited so as to substantially increase the collagen content of the skin corium layer, and the anti-aging effect on the skin can be effectively achieved.

The invention relates to the technical field of microorganisms, in particular to a bifidobacterium animalis subsp. Lactis and application thereof, and particularly provides a bifidobacterium animalis subsp. Lactis BX-BC08 which is beneficial for restoring the microecological balance of the intestinal tract and enhancing the immune barrier function of the intestinal tract. Experiments prove that the bifidobacterium animalis subsp. Lactis BX-BC08 disclosed by the invention can regulate an immune system and relieve excessive immune response, can reduce generation of inflammatory factors and relieve skin inflammation symptoms for autoimmune related diseases such as atopic dermatitis, is relatively good in tolerance to a human body, and greatly reduces adverse reaction of the human body.

The invention discloses a preparation method and permeation promotion application of a high-purity sponge bone needle, and belongs to the technical field of sponge bone needles. Comprising the following steps: cutting a natural sponge into pieces, soaking in deionized water, carrying out ultrasonic oscillation, filtering, and cleaning to obtain a pretreated sponge; carrying out enzymolysis on the pretreated sponge with alkaline protease to obtain a primary zymolyte; and carrying out enzymolysis with ginger protease to obtain a secondary enzymolysis product, and carrying out vacuum freeze drying to obtain the high-purity sponge spicule. The natural sponge is subjected to enzymolysis treatment through alkaline protease and ginger protease, and the high-purity sponge spicule is obtained; wheat oligopeptide is grafted on the surface of a sponge spicule, and giant salamander skin collagen, a pomegranate seed extract, a lonicerae flos extract, a centella asiatica extract, an early celery extract, an iris tectorum extract, an oyster shell extract and calcium chloride mixed treatment materials are loaded, so that the repairing effect on skin inflammation acne is improved.

The invention discloses methotrexate-loaded sulfonated bacterial cellulose / chitosan hydrogel for treating psoriasis and a preparation method of the methotrexate-loaded sulfonated bacterial cellulose / chitosan hydrogel. The method comprises the following steps: firstly, loading methotrexate by using sulfonated bacterial cellulose, and then coupling with chitosan to form the methotrexate-loaded sulfonated bacterial cellulose / chitosan hydrogel. The synthesis method is simple, the prepared methotrexate-loaded sulfonated bacterial cellulose / chitosan hydrogel can promote the transdermal release effect of methotrexate and control the release speed of methotrexate, skin inflammation caused by psoriasis is continuously and effectively relieved, and the methotrexate-loaded sulfonated bacterial cellulose / chitosan hydrogel has good biological safety.

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

This invention provides a transdermal nanoparticle delivery system for skin anti-inflammation, comprising a protein-blue calyx methyl ether-polymer shell capsule composite structure. The protein has an affinity for the skin, blue calyx methyl ether is loaded within the protein, and the polymer layer coats the surface of the protein. The blue calyx methyl ether nanoparticle transdermal delivery system has a size of 30-80 nm, and the polymer shell thickness is 10-35 nm. The surface properties of the polymer shell can be controlled according to the required transdermal delivery depth, enabling the protein to penetrate the skin barrier and be efficiently delivered deep into the skin, where the blue calyx methyl ether is then slowly released, targeting and alleviating skin inflammation. This addresses the drawback of low therapeutic efficacy of blue calyx methyl ether in treating skin inflammation due to unsatisfactory transdermal effects.

The invention relates to application of cembratrienol in preparation of a medicine for preventing and / or treating psoriasis, and belongs to the technical field of biological medicine. The invention provides an application of cembratrienol in preparation of a medicine for preventing / or treating psoriasis. Researches find that cembratrienol can significantly inhibit secretion of inflammatory factors in a psoriasis-like cell model induced by M5; moreover, research finds that cembratrienol can significantly improve the skin lesion condition of an imiquimod-induced psoriasis mouse model, improve the weight loss degree of the psoriasis mouse model, relieve the pruritus condition of the psoriasis mouse model, improve the skin inflammation of the psoriasis mouse model, repair the skin barrier of the psoriasis mouse model, and improve the curative effect of the psoriasis mouse model. The body immune response of the psoriasis mouse model is reduced. Therefore, cembratrienol has a great application prospect in preparation of the medicine for preventing / treating psoriasis.

The invention discloses an application of core proteoglycan or a coding gene thereof as a target spot in preparation of psoriasis treatment drugs, and a series of experiments prove that DCN can effectively protect mouse psoriasis-like dermatitis induced by imiquimod, improve skin scale, erythema, thickening and epidermal abnormal differentiation, enhance the barrier function of skin, improve the curative effect of psoriasis, and improve the curative effect of psoriasis. A large amount of infiltration of inflammatory cells is reduced, and a certain anti-inflammatory effect is achieved. Experimental research shows that the DCN has an obvious drug effect on a psoriasis model, is safe and efficient, has no side effect, is simple in production process and has the potential of realizing medical transformation. And the potential application value of the DCN on other various skin inflammatory diseases can be expanded.

The invention provides a glaucocalyxin A nano transdermal delivery system for skin inflammation resistance, which is of a capsule composite structure of protein, glaucocalyxin A and a polymer shell layer, the protein has an affinity effect on skin, glaucocalyxin A is loaded in the protein, the polymer layer coats the surface of the protein, the size of the glaucocalyxin A nano transdermal delivery system is 30-80nm, and the size of the polymer layer is 30-80nm. And the thickness of the polymer shell layer is 10-35 nm. The surface property of the polymer shell can be regulated and controlled according to the depth requirement of transdermal delivery, so that protein breaks through the skin barrier and is efficiently delivered to the deep position of the skin, the glaucocalyxin A is slowly released, the skin inflammation is relieved in a targeted mode, and the defect that the treatment effect is poor due to the non-ideal transdermal effect when glaucocalyxin A is used for treating the skin inflammation is overcome.

The invention discloses a high-entropy alloy nanoparticle and application thereof. The nanoparticles are formed by specific noble metals, have multienzyme activity, and can effectively remove ROS (reactive oxygen species) at an inflammation part and remodel the free radical steady state of the inflammation part; the skin inflammation reaction can be inhibited by adjusting a JAK-STAT signal channel; skin inflammation caused by psoriasis can be relieved by down-regulating inflammatory factors IL-6, IL-17 and IL-23, and a new treatment scheme is provided for psoriasis treatment.

The invention belongs to the technical field of microorganisms, and particularly relates to an oligopeptide from lactobacillus plantarum extracellular vesicles and application of the oligopeptide. Specifically, the lactobacillus plantarum extracellular vesicles can recover the skin barrier; the expression of proinflammatory factors in a cell inflammation model can be reduced, and a relatively good anti-inflammatory effect is achieved. Metabolome analysis shows that effective substances having effects on skin barrier injury comprise oligopeptide KLQ; kLQ can regulate skin barrier related gene expression in the SDS-induced damaged cell model; and the expression of skin inflammation-related genes in the SDS-induced damaged cell model is regulated, so that the SDS-induced SDS-induced damaged cell model can be used as a medicine for treating skin barrier injury.

The invention relates to a composition with anti-inflammatory and anti-aging effects and application thereof, the composition comprises a dogwood extract, a radix fici simplicissimae extract and a guava extract, the composition can effectively scavenge free radicals, inhibit collagenase activity and inhibit generation of fluorescent AGEs, and the composition has the anti-inflammatory and anti-aging effects. Skin aging and skin laxity and darkness caused by glycosylation reaction are prevented. Meanwhile, by inhibiting NO secretion, the composition relieves skin inflammation reaction and can also improve skin microcirculation. All the components have a synergistic effect, so that the anti-oxidation, anti-inflammatory, anti-aging and anti-saccharification effects are remarkably enhanced, and the skin problems are comprehensively solved. No organic solvent is used in the process, the green and environment-friendly concept is met, the safety and reliability of the extract are ensured, and a mild and efficient solution is provided for anti-aging.

An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.

The present disclosure provides an acne-removing and recurrence-preventing composition suitable for acne-sensitive skin and its application, belonging to the field of cosmetic technology. The present disclosure selects epigallocatechin gallate glucoside, brazilin, Hibiscus sabdariffa flower extract, Ziziphus jojoba bark extract, linseed oil unsaponifiables, and guaiac extract as active ingredients of the acne-removing and recurrence-preventing composition. The active ingredients interact with each other to quickly inhibit the growth of acne-related pathogens and regulate the skin microecology; effectively inhibit skin inflammation throughout the acne process, play a role in preventing and suppressing inflammation, effectively repair the skin barrier, reduce redness, and regulate the skin's oil balance to prevent acne recurrence; in addition, the acne-removing and recurrence-preventing composition also has the effect of removing yellowness, evens skin tone, and improves skin roughness. The acne-removing and recurrence-preventing composition is mild and non-irritating and can be used on sensitive skin, expanding the application range of the acne-removing and recurrence-preventing composition.

The present invention discloses an application of LCE5A as a target in the preparation of a drug for treating inflammatory skin diseases including psoriasis, wherein the LCE5A is mainly expressed on the epidermis; the present invention confirms through a series of experiments that LCE5A can effectively alleviate imiquimod-induced psoriasis-like skin inflammation in mice. The protein can significantly improve the barrier function of mouse skin, inhibit the release of proinflammatory factors and reduce the infiltration of inflammatory cells by regulating the proliferation and differentiation of keratinocytes. This provides important experimental support for the use of LCE5A in the preparation of drugs for skin diseases caused by skin barrier damage, as well as the development of functional skin care products. The experimental results clearly show that LCE5A exhibits significant therapeutic effects in a mouse psoriasis-like inflammation model, and its effect is safe and stable. The protein has a simple extraction and purification process, has good industrial production potential, and lays a solid foundation for clinical application.

The invention discloses spirulina extracellular vesicle hydrogel as well as a preparation method and application thereof. The spirulina extracellular vesicle hydrogel is prepared by separating spirulina extracellular vesicles and loading the spirulina extracellular vesicles on sodium alginate / carboxymethyl chitosan hydrogel, and the method is low in cost, simple, feasible, green and safe. Skin tissue lesions caused by ultraviolet radiation can be effectively prevented and treated by externally applying the hydrogel, and the skin tissue lesions comprise abnormal epidermis thickening, collagenous fiber loss and disorder and the like; skin oxidative stress caused by ultraviolet is inhibited, and the anti-oxidation effect is achieved; the skin inflammation caused by ultraviolet is relieved by inhibiting the generation of proinflammatory factors; as a skin dressing, transdermal noninvasive administration can be realized; good biological safety is shown. The method has a wide application prospect in prevention and treatment of skin ultraviolet injury related diseases by using bioactive materials.

The invention belongs to the technical field of natural products, and provides application of fucoxanthin in preparation of oral anti-alopecia drugs. Animal experiments find that long-term high-fat diet can lead to large-piece shedding of hair accompanied by skin inflammation, and fucoxanthin has a treatment effect on high-fat diet induced mouse back hair shedding and skin inflammation, can obviously relieve high-fat diet induced subcutaneous cholesterol crystal accumulation and sebaceous gland cell hypertrophy, and has the effects of preventing and treating the high-fat diet induced mouse back hair shedding and skin inflammation and preventing and treating the high-fat diet induced mouse back hair shedding and the high-fat diet induced sebaceous gland cell hypertrophy. And skin epidermal hyperplasia and cuticle thickening induced by high fat diet can be improved. Besides, cell experiments also find that fucoxanthin intervention can reduce oleic acid infiltration of the hair follicle stem cells and reduce oleic acid induced death and apoptosis of the hair follicle stem cells, and prove that fucoxanthin has a protection effect on the hair follicle stem cells, has low toxic and side effects on cells and animals as a natural algae extract, and has a good application prospect. Good clinical application prospects are realized.

The invention discloses an application of glucopyranose sulfate galactooligosacharide in preparation of a medicine for treating atopic dermatitis. The glucopyranose galactooligosaccharide can significantly improve the skin condition of a DNCB-induced atopic dermatitis mouse model, including reducing the skin inflammatory factor level, improving the skin barrier function, and reducing the lymph node quality and the number of lymphocytes, and has no abnormal influence on blood routine. The composition has the advantages of small drug application dosage, low pharmaceutical cost, safety, no side effect, strong drug effect and the like, and has a wide application prospect.

The invention discloses a method for evaluating improvement of skin inflammation and aging based on a zebra fish model and application thereof. The method comprises the following steps: S1, establishing a blank group; s2, establishing a model group; s3, establishing a sample group; s4, performing constant-temperature incubation; s5, observing the zebrafish of the blank group, the model group and the sample group under a body type fluorescence microscope, and recording the anti-inflammatory efficiency and the anti-wrinkle efficiency of the zebrafish; and S6, evaluating the skin inflammation and aging improving effect of the sample according to an anti-inflammation and anti-aging calculation formula. The method has the advantages of low cost, short test period, high reproducibility, high visualization degree, intuitive and understandable test result and the like, and can be used for accurately grading the efficacy of the cosmetic raw materials for improving skin inflammation and aging from the whole animal level.

The invention discloses a pharmaceutical composition for treating atopic dermatitis and a preparation method and application of the pharmaceutical composition for treating atopic dermatitis. The pharmaceutical composition comprises matrix vaseline, a humectant, a moistening agent, a repairing agent and an antioxidant. Two lipid components (gamma-linolenic acid and linoleic acid) are supplemented, so that eczema-like dermatitis can be obviously relieved, skin lesion inflammatory cell infiltration is reduced, the content of fatty acid in a skin barrier is recovered, treatment of atopic dermatitis is assisted, and the treatment effect on the atopic dermatitis is remarkable; the pharmaceutical composition disclosed by the invention has the advantages of quick effect on atopic dermatitis, small toxic and side effects, good safety and good medicinal prospect.

The present invention relates to hybrid exosomes, a use of the same, and a preparation method of the same, and the hybrid exosomes provided from the present invention have excellent skin inflammation amelioration, skin wrinkle amelioration, skin moisturization efficacy, and skin regeneration efficacy compared to using hydrangea-derived exosomes and liposomes alone, and thus can be effectively utilized as a cosmetic composition containing the same as an active ingredient. In addition, the hybrid exosomes have better stability and biocompatibility compared to existing exosomes.

The invention belongs to the technical field of cosmetics, and particularly relates to a composition for improving the skin state, a functional hydrogel dressing and application of the functional hydrogel dressing. The composition for improving the skin condition, provided by the invention, is prepared by taking the asiaticoside, the coptis chinensis extracting solution and the purslane extracting solution as core components, and matching the core components with the nicotinamide, the allantoin, the ceramide and the sodium hyaluronate. The composition provided by the invention achieves the effects of repairing the skin barrier, improving the skin state and adjusting the skin color through multiple mechanisms of resisting skin inflammation, resisting oxidation, inhibiting tyrosinase activity and the like. The composition is applied to the functional hydrogel dressing, so that the antibacterial activity and the skin repairing capacity of the composition can be further improved, the use frequency can be reduced, and the composition has a wide development prospect.

The invention relates to a cosmetic composition, advantageously an ecobiological cosmetic composition, comprising: - polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by general formula (I), in which: - R1 represents a hydrogen atom, an acyl radical or an acyloxy radical; and - R2 represents the side chain of an α-amino acid selected from the group consisting of: tryptophan, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine. The invention also relates to the use of the cosmetic composition for combatting skin redness and / or skin ageing; to the use thereof for preventing and / or combatting cutaneous hypervascularisation and / or skin inflammation and / or rosacea; and to a method for selecting compounds suitable for preventing and / or combatting these conditions.

The present invention relates to a cosmetic composition, advantageously an eco-biological cosmetic composition, comprising: - polyglutamic acid or a salt thereof; and - at least one peptide derivative represented by the general formula (I) in which: - R1 represents a hydrogen atom, an acyl radical or an acyloxy radical; and - R2 represents the side chain of an alpha-amino acid chosen from the group consisting of phenylalanine, glutamic acid, arginine, cysteine, methionine, histidine and tyrosine. The present invention also relates to the use of said cosmetic composition for combating skin redness and / or skin aging; to its use for preventing and / or combating cutaneous vascular hyperproliferation and / or cutaneous inflammation and / or rosacea; and to a method for selecting compounds suitable for preventing and / or combating these pathologies.

The present disclosure relates to the use of MrgprX2 antagonists in the treatment of inflammatory conditions, for example, skin inflammatory conditions. The present invention also relates to pharmaceutical compositions comprising a MrgprX2 antagonist and a pharmaceutically acceptable carrier for topical or oral administration.

The invention discloses application of a CD36 inhibitor in preparation of a medicine for treating psoriasis, and belongs to the technical field of biological medicine. Experiments prove that the ointment containing the CD36 inhibitor can significantly reduce the expression level of psoriasis related inflammatory factors CXCL5 / CXCL8 and CCL20, and reduce the local infiltration of CCR6 + T cells and neutrophils. The CD36 inhibitor ointment can inhibit secretion of inflammatory chemotactic factors related to keratinocyte psoriasis so as to effectively relieve psoriasis-like dermatitis induced by IMQ, and can be used for preparing local external medicines for treating psoriasis.

This invention relates to the field of peptide technology, and more particularly to a cyclic tetrapeptide compound, its preparation method, and its applications. The peptide compound has the structure shown in Formula I, or its stereoisomer or salt thereof: c(AA1-AA2-AA3-AA4), Formula I. The cyclic tetrapeptide compound can simultaneously inhibit the release of the inflammatory factor IL-6 and effectively scavenge reactive oxygen species DPPH, ABTS, and PTIO. It can effectively inhibit the production of reactive oxygen species, alleviate skin inflammation, and improve skin condition, showing great promise in the fields of anti-inflammatory and antioxidant applications.

The present application provides a marine alga composition with soothing and repairing effects, which combines sea fennel extract and d. capillata extract, inhibits skin inflammation, promotes expression of skin protective proteins, solves skin inflammation, and has excellent soothing and moisturizing and repairing effects, fundamentally solves a series of problems of the skin, has high and efficient effects, and has a good application prospect.

The invention belongs to the technical field of microorganisms, and particularly relates to phospholipid from extracellular vesicles of phytobacterium plantarum and application of the phospholipid. Specifically, the plant lactobacillus extracellular vesicles can restore the skin barrier; the expression of proinflammatory factors in a cell inflammation model can be reduced, and a relatively good anti-inflammatory effect is achieved. Through metabolome analysis, it is found that effective substances having effects on skin barrier injury comprise phospholipid 1-palmitoyl-sn-glycerol-3-phosphorylcholine (PC, 16: 0 / 0: 0); experiments prove that PC (16: 0 / 0: 0) can regulate the expression of skin barrier related genes in the SDS-induced damaged cell model; and the expression of skin inflammation-related genes in the SDS-induced damaged cell model is regulated, so that the SDS-induced SDS-induced damaged cell model can be used as a medicine for treating skin barrier injury.

The invention provides a preparation method of a purslane extract as well as a product and application of the purslane extract, and belongs to the technical field of cosmetics. The preparation method comprises the following steps: (1) preparing purslane powder; (2) performing ultrasonic-assisted extraction on the mixed solution, and filtering to obtain filtrate 1 and filter residues; (3) performing enzymolysis extraction, and filtering to obtain filtrate 2; (4) mixing the filtrate 1 and the filtrate 2, adding a clarifying agent, stirring, standing and filtering to obtain an extracting solution; and (5) decoloring the obtained extracting solution, carrying out rotary evaporation concentration, and freeze-drying to obtain the purslane extract. The portulaca oleracea extract obtained by the method provided by the invention is high in yield, relatively high in total flavone and total polyphenol content and extremely low in protein content, so that the portulaca oleracea extract has better anti-inflammatory and anti-allergy effects, can better relieve skin inflammation when being used in cosmetics, and achieves the anti-inflammatory, repairing and soothing effects.